caa a22 4500 44588925X CHVBK 20180317145610.0 cr unu---uuuuu 170323e20110201xx s 000 0 eng 10.1007/s00535-010-0334-1 doi (NATIONALLICENCE)springer-10.1007/s00535-010-0334-1 Proton pump inhibitor versus prokinetic therapy in patients with functional dyspepsia: is therapeutic response predicted by Rome III subgroups? [Elektronische Daten] [Yao-Chun Hsu, Jyh-Ming Liou, Tzeng-Huey Yang, Wei-Lun Hsu, Hwai-Jeng Lin, Huei-Tang Wu, Jaw-Town Lin, Hsiu-Po Wang, Ming-Shiang Wu] Background: The comparative effectiveness of proton pump inhibitor versus prokinetic therapy in relieving the symptoms of patients with functional dyspepsia remains unknown. Whether the Rome III subgroups predict therapeutic response has not been investigated. Methods: This was an open-label, parallel randomized controlled trial. A total of 329 adult outpatients fulfilling the Rome III criteria for functional dyspepsia were randomly allocated to receive either lansoprazole 30mg once daily (n=166) or mosapride 5mg thrice daily (n=163) for 2weeks. Enrolled patients were evaluated with the validated Hong Kong Index questionnaire for symptom severity at baseline and at the end of the trial. The primary outcome was symptom relief as defined by the Hong Kong Index, and the secondary outcome was decrease of symptom scores. Post-hoc multivariate logistic regression analysis was conducted to identify independent predictors for therapeutic response. Results: After 2-week therapy, 50.6% (84/166) and 47.85% (78/163) of the patients treated with lansoprazole and mosapride, respectively, achieved significant symptom relief (odds ratio 1.12, 95% confidence interval 0.72-1.72, p=0.62). Differences in decreases of symptom scores between lansoprazole and mosapride receivers were also insignificant (−0.08, 95% confidence interval −1.25 to 1.09, p=0.89). Therapeutic responses to either pharmacotherapy did not differ in the subgroup of patients fulfilling the criteria for epigastric pain syndrome (n=256) or in those fulfilling the criteria for postprandial distress syndrome (n=161). Multivariate logistic regression confirmed that the treatment allocation and Rome III subgroup were unrelated to treatment outcome. Conclusions: The effectiveness of proton pump inhibitor therapy and that of prokinetic therapy in functional dyspepsia are not different, and cannot be predicted by Rome III subgroups (ClinicalTrials.gov number, NCT00663897). Springer, 2010 Functional dyspepsia nationallicence Lansoprazole nationallicence Mosapride nationallicence Epigastric pain syndrome nationallicence Postprandial distress syndrome nationallicence Hsu Yao-Chun Department of Internal Medicine, E-Da Hospital, I-Shou University, Kaohsiung, Taiwan aut Liou Jyh-Ming Department of Internal Medicine, National Taiwan University Hospital, 7, Chung-Shan S. Rd, 100, Taipei, Taiwan aut Yang Tzeng-Huey Division of Gastroenterology, Department of Medicine, Lotung Poh-Ai Hospital, Ilan, Taiwan aut Hsu Wei-Lun Division of Gastroenterology, Department of Medicine, Lotung Poh-Ai Hospital, Ilan, Taiwan aut Lin Hwai-Jeng Division of Gastroenterology, Department of Medicine, Changhua Christian Hospital, Changhua, Taiwan aut Wu Huei-Tang Division of Gastroenterology, Department of Medicine, Lotung Poh-Ai Hospital, Ilan, Taiwan aut Lin Jaw-Town Department of Internal Medicine, E-Da Hospital, I-Shou University, Kaohsiung, Taiwan aut Wang Hsiu-Po Department of Internal Medicine, National Taiwan University Hospital, 7, Chung-Shan S. Rd, 100, Taipei, Taiwan aut Wu Ming-Shiang Department of Internal Medicine, National Taiwan University Hospital, 7, Chung-Shan S. Rd, 100, Taipei, Taiwan aut Journal of Gastroenterology Springer Japan 46/2(2011-02-01), 183-190 0944-1174 46:2<183 2011 46 535 https://doi.org/10.1007/s00535-010-0334-1 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s00535-010-0334-1 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Hsu Yao-Chun Department of Internal Medicine, E-Da Hospital, I-Shou University, Kaohsiung, Taiwan aut NATIONALLICENCE 700 1- Liou Jyh-Ming Department of Internal Medicine, National Taiwan University Hospital, 7, Chung-Shan S. Rd, 100, Taipei, Taiwan aut NATIONALLICENCE 700 1- Yang Tzeng-Huey Division of Gastroenterology, Department of Medicine, Lotung Poh-Ai Hospital, Ilan, Taiwan aut NATIONALLICENCE 700 1- Hsu Wei-Lun Division of Gastroenterology, Department of Medicine, Lotung Poh-Ai Hospital, Ilan, Taiwan aut NATIONALLICENCE 700 1- Lin Hwai-Jeng Division of Gastroenterology, Department of Medicine, Changhua Christian Hospital, Changhua, Taiwan aut NATIONALLICENCE 700 1- Wu Huei-Tang Division of Gastroenterology, Department of Medicine, Lotung Poh-Ai Hospital, Ilan, Taiwan aut NATIONALLICENCE 700 1- Lin Jaw-Town Department of Internal Medicine, E-Da Hospital, I-Shou University, Kaohsiung, Taiwan aut NATIONALLICENCE 700 1- Wang Hsiu-Po Department of Internal Medicine, National Taiwan University Hospital, 7, Chung-Shan S. Rd, 100, Taipei, Taiwan aut NATIONALLICENCE 700 1- Wu Ming-Shiang Department of Internal Medicine, National Taiwan University Hospital, 7, Chung-Shan S. Rd, 100, Taipei, Taiwan aut NATIONALLICENCE 773 0- Journal of Gastroenterology Springer Japan 46/2(2011-02-01), 183-190 0944-1174 46:2<183 2011 46 535 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer